We assessed 11 adjuvants and adjuvant combinations, in different stages of pre-clinical and clinical development, together with an adenoviral-vectored vaccine targeting the malaria pre-erythrocytic stage Ad-ME.TRAP, for an improved protective efficacy against sporozoite challenge. Here, MMP12 is linked to malaria.